D4 receptor Inhibitors
1 drugsAbout D4 receptor
The D4 receptor is a dopamine receptor family member and a G protein-coupled receptor (GPCR) crucial in neurotransmission. It influences various physiological processes within the central nervous system (CNS).
The D4 receptor's involvement in dopamine signaling pathways makes it a therapeutic target for CNS disorders. Currently, there is no genetic evidence directly linking the D4 receptor to specific diseases.
ONAPGO is the only FDA-approved drug targeting the D4 receptor, a small molecule approved in 2025. MDD US is the sole company with an approved drug for this target, addressing CNS indications.
Top D4 receptor Drugs
MDD US is the only company with an approved drug targeting the D4 receptor.
Low competition presents an opportunity, but also indicates potential challenges in the target's validation.
D4 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets D4 receptor, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
D4 receptor Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on D4 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 | 0% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
D4 receptor Drug Approval Timeline (2025 - 2025)
The first and only drug, ONAPGO, was approved in 2025, representing a short approval span of 1 year.
Recent approval suggests renewed interest, but limited history indicates uncertainty in long-term success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on D4 receptor. A trial counts if an approved drug acting on D4 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.